AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16321485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 15042278 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 23
Study 15042278 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 23
Study 11122838 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (unconjugated anti-CD20 monoclonal antibody)
Number of subjects: 0
Study 11122838 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokines (e.g., interferon-alpha, interleukin-2, interleukin-12)
Number of subjects: 0
Study 11122838 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioimmunotherapy
Number of subjects: 0
Study 11122838 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine strategies
Number of subjects: 0
Study 11122838 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplant
Number of subjects: 0
Study 11122838 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen-presenting cells (dendritic cells)
Number of subjects: 0
Study 9062869 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin treatment (0.5 mg at bedtime for 7 days)
Number of subjects: 21
Study 9062869 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin treatment (50 mg daily at bedtime for 37 days)
Number of subjects: 21
Study 9062869 — intervention group
Group type: COMPARATOR
Intervention: Placebo (at bedtime for 7 days)
Number of subjects: 21
Study 8366176 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg cyclosporine
Number of subjects: 24
Study 8366176 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 960 mg three times daily
Number of subjects: 24
Study 8366176 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of cyclosporine and aspirin
Number of subjects: 24
Study 3733279 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand A
Number of subjects: 12
Study 3733279 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand B
Number of subjects: 12
Study 3733279 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand C
Number of subjects: 12
Study 3733279 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dipyridamole
Number of subjects: 12
Study 3733279 — intervention group
Group type: COMPARATOR
Intervention: All brands (A, B, C)
Number of subjects: 12
Study 28767552 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept
Number of subjects: 79
Study 28767552 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal bevacizumab
Number of subjects: 79
Study 26936601 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-enhancing dietary supplement for 7 days before and 5 days after surgery
Number of subjects: 128
Study 26936601 — intervention group
Group type: COMPARATOR
Intervention: Dietary advice
Number of subjects: 128
Study 26936601 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-enhancing dietary supplement
Number of subjects: 128
Study 25898762 — intervention group
Group type: EXPERIMENTAL
Intervention: Foundation products with hygroscopic moisturizing ingredients
Number of subjects: 0
Study 25898762 — intervention group
Group type: COMPARATOR
Intervention: Foundation products without hygroscopic moisturizing ingredients
Number of subjects: 0
Study 22480696 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm children
Number of subjects: 69
Study 22480696 — intervention group
Group type: COMPARATOR
Intervention: Full-term controls
Number of subjects: 69
Study 20465854 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training Group (STG) - high-intensity isometric neck strengthening exercises with an elastic band
Number of subjects: 180
Study 20465854 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training Group (ETG) - lighter dynamic neck muscle training
Number of subjects: 180
Study 20465854 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - received a single session of guidance on stretching exercises
Number of subjects: 180
Study 17905023 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine lollipop
Number of subjects: 50
Study 17905023 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine spray
Number of subjects: 50
Study 15343354 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Reduction intervention
Number of subjects: 1157
Study 15343354 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 1157
Study 12221879 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofelin (2.6 +/- 0.15 micrograms/kg)
Number of subjects: 28
Study 12221879 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl, 20.0)
Number of subjects: 28
Study 10574584 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate treatment
Number of subjects: 6082
Study 10574584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6082
Study 7787157 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg h.s.
Number of subjects: 121
Study 7787157 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg h.s.
Number of subjects: 121
Study 7787157 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg b.i.d.
Number of subjects: 121
Study 2156886 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic porcine BNP (2 pmol/kg.min)
Number of subjects: 8
Study 538766 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame in solution (100 mg/kg body weight)
Number of subjects: 6
Study 538766 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame in slurry (100 mg/kg body weight)
Number of subjects: 6
Study 538766 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame in solution and slurry (100 mg/kg body weight)
Number of subjects: 6
Study 31524020 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded activity
Number of subjects: 89
Study 31524020 — intervention group
Group type: COMPARATOR
Intervention: Other elements of CBT
Number of subjects: 89
Study 27806969 — intervention group
Group type: EXPERIMENTAL
Intervention: Summer camp for 2 weeks and 4 repetition weekends
Number of subjects: 90
Study 27806969 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle school including 4 days family education
Number of subjects: 90
Study 27806969 — intervention group
Group type: EXPERIMENTAL
Intervention: Summer camp
Number of subjects: 90
Study 25993805 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound DCR (1.8 g · d(‐1))
Number of subjects: 79
Study 25993805 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium (75 mg · d(‐1))
Number of subjects: 79
Study 24261608 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin 100 mg intravenously once a day for 14 days
Number of subjects: 260
Study 24261608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 24261608 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin
Number of subjects: 260
Study 21443356 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 1401
Study 19696660 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of 75% fucoidan capsules for 12 days
Number of subjects: 20
Study 19696660 — intervention group
Group type: COMPARATOR
Intervention: 3 g of guar gum capsules for 12 days
Number of subjects: 20
Study 16419441 — intervention group
Group type: EXPERIMENTAL
Intervention: High communal-learning context
Number of subjects: 78
Study 16419441 — intervention group
Group type: COMPARATOR
Intervention: Low communal-learning context
Number of subjects: 78
Study 12923013 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand held echocardiographic device
Number of subjects: 98
Study 12923013 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wave Doppler measurements
Number of subjects: 98
Study 10475182 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (30-50 mg according to body weight)
Number of subjects: 16949
Study 10475182 — intervention group
Group type: COMPARATOR
Intervention: Alteplase (<= 100 mg)
Number of subjects: 16949
Study 10475182 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 16949
Study 10475182 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 16949
Study 8557121 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro fertilization and embryo transfer (IVF-ET)
Number of subjects: 0
Study 8557121 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH-a)
Number of subjects: 0
Study 8557121 — intervention group
Group type: COMPARATOR
Intervention: Purified FSH preparations
Number of subjects: 0
Study 8557121 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies for OHSS prevention (intravenous albumin, triggering with GnRH-a, withholding menotropin therapy)
Number of subjects: 0
Study 8557121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreservation of all embryos
Number of subjects: 0
Study 8557121 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF-ET
Number of subjects: 0
Study 1816845 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% C31G-containing toothpaste
Number of subjects: 96
Study 1816845 — intervention group
Group type: EXPERIMENTAL
Intervention: C31G-containing toothpaste in different concentrations and combinations with and without fluoride
Number of subjects: 96
Study 6175803 — intervention group
Group type: EXPERIMENTAL
Intervention: Alinidine 80 mg
Number of subjects: 0
Study 6175803 — intervention group
Group type: EXPERIMENTAL
Intervention: Alinidine 40 mg once daily
Number of subjects: 0
Study 6175803 — intervention group
Group type: EXPERIMENTAL
Intervention: Alinidine 40 mg twice daily
Number of subjects: 0
Study 6175803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6175803 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 40 mg
Number of subjects: 0
Study 6175803 — intervention group
Group type: COMPARATOR
Intervention: Clonidine 0.1 mg
Number of subjects: 0
Study 28411006 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% minocycline mouth rinse
Number of subjects: 14
Study 28411006 — intervention group
Group type: COMPARATOR
Intervention: 0.2% minocycline mouth rinse
Number of subjects: 14
Study 27261170 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (cycling 3×/week for 30min at moderate to vigorous intensity)
Number of subjects: 83
Study 27261170 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (supervised myofascial release training 3×/week, approx. 30min)
Number of subjects: 83
Study 27261170 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 83
Study 24097260 — intervention group
Group type: COMPARATOR
Intervention: No self-harm at baseline
Number of subjects: 2042
Study 24097260 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors identified
Number of subjects: 2042
Study 24097260 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences
Number of subjects: 2042
Study 21898040 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX), 400 mg/tid from 24 h before to 24 h after coronary angioplasty
Number of subjects: 286
Study 21898040 — intervention group
Group type: COMPARATOR
Intervention: Control group with routine treatment and no PTX
Number of subjects: 286
Study 18822413 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release (ER) niacin 1000 mg/day
Number of subjects: 107
Study 18822413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 17996517 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg)
Number of subjects: 566
Study 17996517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 566
Study 16255470 — intervention group
Group type: EXPERIMENTAL
Intervention: COX‐2 inhibitors (COX‐2i)
Number of subjects: 127
Study 12501222 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 287
Study 12501222 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 75 mg twice daily plus omeprazole 20 mg daily
Number of subjects: 287
Study 12501222 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 287
Study 12501222 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac plus omeprazole
Number of subjects: 287
Study 9614767 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal challenge test with allergen
Number of subjects: 100
Study 9614767 — intervention group
Group type: COMPARATOR
Intervention: Nasal challenge test with placebo
Number of subjects: 100
Study 9614767 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 atopic subjects not sensitized to allergens)
Number of subjects: 100
Study 9614767 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 healthy subjects)
Number of subjects: 100
Study 7652027 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral 95 dB SPL white-noise stimulation (S2)
Number of subjects: 7
Study 7652027 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual attention task (S3)
Number of subjects: 7
Study 7652027 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined stimulation (S4)
Number of subjects: 7
Study 2649340 — intervention group
Group type: EXPERIMENTAL
Intervention: Premeal injections of short‐acting insulin and intermediate‐acting insulin at bedtime (using Novopen)
Number of subjects: 18
Study 2649340 — intervention group
Group type: COMPARATOR
Intervention: Conventional three times daily injection regimen
Number of subjects: 18
Study 334207 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidoxime 75 mg
Number of subjects: 0
Study 334207 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidoxime 100 mg
Number of subjects: 0
Study 334207 — intervention group
Group type: COMPARATOR
Intervention: Dihydrocodeine 50 mg
Number of subjects: 0
Study 31724474 — intervention group
Group type: EXPERIMENTAL
Intervention: Children living in villages
Number of subjects: 1080
Study 31724474 — intervention group
Group type: COMPARATOR
Intervention: Overall population of children studied
Number of subjects: 1080
Study 31250285 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS treatment
Number of subjects: 29
Study 31250285 — intervention group
Group type: COMPARATOR
Intervention: SHAM treatment
Number of subjects: 29
Study 28481614 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive addiction/housing case management (AHCM)
Number of subjects: 181
Study 28481614 — intervention group
Group type: COMPARATOR
Intervention: Housing support group (HSG)
Number of subjects: 181
Study 28481614 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 181
Study 27136904 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol/gestodene contraceptive patch
Number of subjects: 36
Study 24206154 — intervention group
Group type: EXPERIMENTAL
Intervention: PTT alone ('plastic' condition)
Number of subjects: 145
Study 24206154 — intervention group
Group type: EXPERIMENTAL
Intervention: SP‐PTT hybrid with an SP who did not engage in any superfluous conversation ('perfunctory' condition)
Number of subjects: 145
Study 24206154 — intervention group
Group type: EXPERIMENTAL
Intervention: SP‐PTT hybrid with an SP who was trained to offer small talk and banter ('pleasant' condition)
Number of subjects: 145
Study 24206154 — intervention group
Group type: COMPARATOR
Intervention: Communication skills across all groups
Number of subjects: 145
Study 24206154 — intervention group
Group type: COMPARATOR
Intervention: Technical skills scores among groups
Number of subjects: 145
Study 21241520 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol challenge
Number of subjects: 28
Study 19951541 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified NPWT (gauze + continuous suction with hospital central negative pressure -10.64 kPa for 24 hs)
Number of subjects: 44
Study 19951541 — intervention group
Group type: COMPARATOR
Intervention: Conventional NPWT (sponge + interrupted suction with purpose-designed suction appliance -16.63 kPa for 24 hs)
Number of subjects: 44
Study 19951541 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified NPWT
Number of subjects: 44
Study 17075662 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-integrated patient-controlled epidural analgesia (CI-PCEA)
Number of subjects: 40
Study 17075662 — intervention group
Group type: COMPARATOR
Intervention: Continuous Epidural Infusion (CEI)
Number of subjects: 40
Study 14564324 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 1379
Study 11324201 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental health education involving teachers
Number of subjects: 430
Study 11324201 — intervention group
Group type: COMPARATOR
Intervention: Dental health education for children alone
Number of subjects: 430
Study 11324201 — intervention group
Group type: COMPARATOR
Intervention: Dental health education for children with parents
Number of subjects: 430
Study 8680050 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) with cyclosporine and maintenance corticosteroids
Number of subjects: 0
Study 8680050 — intervention group
Group type: COMPARATOR
Intervention: High-dose intravenous corticosteroids (i.v. steroids) and conventional triple therapy
Number of subjects: 0
Study 1740541 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal delivery system (TDS) with 20 mg GTN, applied for 4 successive days
Number of subjects: 10
Study 1740541 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal delivery system (TDS) releasing 15 mg GTN/day
Number of subjects: 10
Study 1740541 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal delivery system (TDS)
Number of subjects: 10
Study 1740541 — intervention group
Group type: COMPARATOR
Intervention: Sublingually administered GTN
Number of subjects: 10
Study 6377291 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education program
Number of subjects: 115
Study 6377291 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood pressure for 6 months
Number of subjects: 115
Study 6377291 — intervention group
Group type: EXPERIMENTAL
Intervention: Both health education and self-monitoring
Number of subjects: 115
Study 6377291 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 115
Study 31835036 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-cell genomics
Number of subjects: 12715
Study 28513525 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with soft tissue manipulation therapy
Number of subjects: 0
Study 28513525 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (triple therapy of needle, moxibustion, and cupping jar)
Number of subjects: 0
Study 27110915 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 1125
Study 27110915 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery (CRS) and HIPEC
Number of subjects: 1125
Study 27110915 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPEC
Number of subjects: 1125
Study 24823671 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive arm (second-look surgery)
Number of subjects: 216
Study 24823671 — intervention group
Group type: COMPARATOR
Intervention: Conventional arm (no second-look surgery)
Number of subjects: 216
Study 22038623 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing (BiV) ON
Number of subjects: 11
Study 22038623 — intervention group
Group type: COMPARATOR
Intervention: Biventricular pacing (BiV) OFF
Number of subjects: 11
Study 19464558 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated H7N3 virus vaccine (10^7.5 TCID50 administered by nasal spray, 2 doses, 5 weeks apart)
Number of subjects: 21
Study 19464558 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated H7N3 virus vaccine (first dose)
Number of subjects: 21
Study 19464558 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated H7N3 virus vaccine (second dose)
Number of subjects: 21
Study 19464558 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated H7N3 virus vaccine
Number of subjects: 21
Study 17699438 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy (CRRT)
Number of subjects: 0
Study 17699438 — intervention group
Group type: COMPARATOR
Intervention: Intermittent hemodialysis (IHD)
Number of subjects: 0
Study 14992920 — intervention group
Group type: EXPERIMENTAL
Intervention: TachoComb
Number of subjects: 80
Study 14992920 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 5,000 IU
Number of subjects: 80
Study 14992920 — intervention group
Group type: EXPERIMENTAL
Intervention: TachoComb and Dalteparin
Number of subjects: 80
Study 14992920 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical hemostasis
Number of subjects: 80
Study 14992920 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 4,000 IU
Number of subjects: 80
Study 12047396 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide 60 mg plus metformin 1000 mg b.i.d.
Number of subjects: 467
Study 12047396 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide 120 mg plus metformin 1000 mg b.i.d.
Number of subjects: 467
Study 12047396 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide 120 mg plus metformin 1000 mg b.i.d. in patients with HbA1c > 9.5%.
Number of subjects: 467
Study 12047396 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide 60 mg in patients with low HbA1c levels (<or= 8%) at baseline.
Number of subjects: 467
Study 12047396 — intervention group
Group type: COMPARATOR
Intervention: Metformin 1000 mg b.i.d.
Number of subjects: 467
Study 11317199 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg o.d.
Number of subjects: 9
Study 11317199 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg o.d.
Number of subjects: 9
Study 11317199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 11317199 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (Losartan + Enalapril)
Number of subjects: 9
Study 9207352 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% undecylenic acid cream
Number of subjects: 573
Study 11767425 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 0.5%
Number of subjects: 40
Study 11767425 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 1%
Number of subjects: 40
Study 11767425 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 1.5%
Number of subjects: 40
Study 11767425 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 40
Study 3304029 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (mean dose 167 mg/day)
Number of subjects: 21